Each one in plain English, with the numbers worked through for a shareholder.
31 Jan 2025quarterly activities report▼ BadMajor
December quarter: about 7,900t LCE in ponds, cash A$3.6M, Chemphys US$3M received. First Phase 1 production is now targeted for H1 2026, later than the H2 2025 target, with timing adjusted for financing and offtake talks. Prepayment facility still targets Q1 2025 close.
Secondary trading notice for 42,835,724 shares issued on 30 January 2025 under a placement. Administrative only; the text gives no price or buyer. It may relate to the Chemphys placement (inference).
Candelas resource grows more than 150% to 1.6Mt LCE (from 685kt in 2019), lifting Galan's total to 9.5Mt LCE. HMW is unchanged at 7.9Mt, which differs from the 8.6Mt total booked in March 2024. Galan says it ranks in the global top 10.
28 Jan 2025capital raising announcement▲ GoodMajor
Galan received the US$3M Chemphys placement money via affiliate Latam Resources, after shareholders approved it at the 15 November 2024 AGM. Funds go to Phase 1 work. The offtake prepayment facility is still unsigned, targeting close in Q1 2025.
Replacement of the 6 January Phase 2 permit announcement, with a corrected Wood Mackenzie cost curve chart, an expanded footer and an ASX Listing Rule 5.19 statement. No change to the permit news.
Catamarca granted the full Phase 2 mining permit for up to 21,000tpa LCE at HMW, a permit Galan had been pursuing. Expansion still needs project finance and Phase 1 delivery. The company says Phase 2 would be cash flow positive at current prices.
Sixth Acuity at-the-market draw: A$1.8M from 15M shares at A$0.12, equal to the 15-day VWAP, for working capital. The price is above the August A$0.1222 draw but far below the A$0.283 of the first draw in May.
What it means for a shareholder
15.0m new shares at A$0.120 to raise about A$1.8m. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
Secondary trading notice for the 15,000,000 shares issued on 27 December 2024 under the Acuity at-the-market deed. Administrative only; repeats the draw announced the same day.
The deadline for Chemphys's A$4.5M placement participation is extended from 31 December 2024 to 24 January 2025. The prepayment facility is still not signed; both parties now target financial close in the first quarter of 2025, so timing has slipped.
Secondary trading notice for 4,800,000 shares issued on 20 November 2024 under the Acuity at-the-market deed. Administrative only; the text gives no price or amount raised.
September quarter: over 6,000t LCE in ponds, Phase 1 about 45% complete, first production still targeted H2 2025 at 4,000tpa. Galan applied for Argentina's RIGI incentive regime on 30 October. Cash was A$2.4M, with A$14M raised after quarter end.
Secondary trading notice for 5,911,399 shares issued on 24 October 2024 under a placement to institutional and sophisticated investors. Administrative only; the text gives no price or total raised.
16 Oct 2024capital raising announcement▲ GoodMajor
The entitlement offer closed fully subscribed, raising A$13.3M at A$0.105. Eligible holders applied for 60.2M shares and the full 66.5M shortfall was taken up. This completes the A$25M raising begun in September; shares issue 17 October.
What it means for a shareholder
60.2m new shares at about A$0.2209 to raise about A$13.3m. Shares on issue before the raise aren't in the record, so the dilution can't be worked out.
Notice of the annual general meeting to be held 15 November 2024 in Subiaco, with proxies due 13 November. Physical copies are not mailed. The visible text is procedural; the resolutions are truncated and not shown.
Annual report for the year to 30 June 2024, with Hall Chadwick as auditor. The visible text covers directors and their holdings, for example the MD holds 21.65M shares. Financial results are not shown in the extract.
Entitlement offer closing date extended one week to 10 October 2024, with shares to be issued 17 October. Directors cite mailing delays and giving holders time to read the 30 June annual report.
Appendix 4G and corporate governance statement for FY2024, confirming the governance statement is current at 27 September 2024. Administrative compliance form with no new business information.
Secondary trading notice for 19,863,770 shares issued on 20 September 2024 to a contractor for services. Administrative only; the text gives no value for the shares.
Entitlement offer booklet: 1 new share for every 4 held at A$0.105, raising about A$13.3M before costs, closing 3 October 2024, with a shortfall facility. It is not underwritten and carries risk factors. It repeats the terms already announced.
Letter telling ineligible (mostly overseas) shareholders they cannot take part in the A$0.105 entitlement offer, and their entitlements will lapse with no payment. Administrative; no new terms.
Letter to eligible shareholders on the 1-for-4 non-renounceable entitlement offer at A$0.105, open 18 September to 3 October 2024, with a shortfall facility. Entitlements not taken up lapse without value. It repeats terms already announced.
Galan retracts pages 8 and 9 of its 10 September capital raising presentation, as the peer comparison tables do not meet ASX guidelines. Investors should not rely on them. Correction only; no new information.
Capital raising presentation supporting the A$0.105 placement and entitlement offer. The visible text is disclaimers and competent person statements; no new figures are shown. Pages 8 and 9 were retracted the next day.
Galan raises about A$12M via a placement at A$0.105, plus a 1-for-4 entitlement offer for up to A$13.3M at the same price. Chemphys takes about A$4.5M, conditional on definitive agreements. Phase 1 is cut to an initial 4,000tpa LCE; first production stays H2 2025.
Fifth Acuity at-the-market draw: A$600k from 4.8M collateral shares at A$0.125, a 7.1% discount to the 15-day VWAP, for working capital. The issue price is still well below the A$0.283 of the first draw in May.
Non-binding MOU with Chengdu Chemphys: 23,000t LCE of lithium chloride over the first five years of HMW Phase 1, plus a US$40M offtake prepayment facility. It is subject to definitive agreements, approvals and due diligence. The company also says it could not proceed with the November 2023 offtake/financing option (Glencore term sheet, inferred).